PTAFR and ovarian carcinoma: The first evidence indicating the crosstalk between the PAFR and EGFR pathways came from the earlier report demonstrating that PAF treatment to ovarian cancer cell lines caused an increased phosphorylation of EGFR and its downstream signaling axis Src (proto-oncogene tyrosine-protein kinase)/FAK (focal adhesion kinase)/paxillin as well as the activation of PI3K and cyclin D1, which are involved in cell proliferation, and matrix metalloproteinases (MMPs) (MMP2 and MMP9), which are involved in cell invasion [34].